• Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock
Investing

Why analysts are not impressed with Trump’s ‘Great Healthcare Plan’

by January 19, 2026
written by January 19, 2026

The Trump administration on Thursday unveiled what it called the “Great Healthcare Plan,” a broad framework aimed at addressing healthcare affordability, drug prices, and insurance transparency.

While the White House described the plan as a decisive step toward reform, analysts and healthcare policy experts largely characterized it as lacking detail, politically constrained, and unlikely to deliver meaningful near-term relief.

The framework arrives amid heightened concern over rising healthcare costs, particularly as enhanced Affordable Care Act (ACA) subsidies expired last year, driving up premiums and deductibles for millions of Americans.

Thursday was also the final day of open enrollment for Obamacare plans, underscoring the timing and political sensitivity of the announcement.

A broad framework with limited specifics

According to the White House, the Great Healthcare Plan rests on four pillars: drug price reforms, health insurance reforms, price transparency for healthcare costs, and fraud protections and safeguards.

Elements highlighted by the administration include funding for health savings accounts, transparency requirements for insurers and providers to publicly post prices, and a call for Congress to codify pricing deals President Trump has made with pharmaceutical companies.

Dr. Mehmet Oz, Trump’s administrator for the Centers for Medicare and Medicaid Services, said during a call with the reporters that “Instead just papering over the problems, we have gotten into this ‘Great Healthcare Plan’ a framework that we believe will help Congress create legislation that will address the challenges”.

President Trump echoed that urgency in the call accompanying the plan’s release, saying he is “calling on Congress to pass this framework into law without delay,” adding that lawmakers “have to do it right now so that we can get immediate relief to the American people.”

However, when pressed for policy specifics, administration officials described the proposal as a “broad framework,” offering few details on implementation or legislative pathways.

Analysts see familiar ideas and political hurdles

Market analysts and policy experts were notably skeptical.

Spencer Perlman, director of healthcare research at Veda Partners, said in a MarketWatch report that the plan appears designed to signal action rather than deliver results.

“We think it is intended to demonstrate that the White House is doing ‘something’ about affordability and healthcare prices, but we believe the policies either stand little chance of being enacted by the current Congress or will have a minimal impact if enacted,” he wrote in a note.

Others echoed that view.

“Their ideas are nothing new, nothing unexpected, pretty challenging to implement,” said Kim Monk, a healthcare policy analyst at Capital Alpha Partners.

“I’m not seeing anything earth-changing.” Raymond James analyst Chris Meekins described the proposal as “a retread of previously advocated-for positions,” adding that “there is no legislative path forward for much of it, in our view.”

Healthcare policy researchers also warned that the plan does not address the most immediate pressure point: rising ACA premiums.

Cynthia Cox, a senior vice president at KFF, said in an npr report that the framework “looks much more like a compilation of Republican ideas” and “doesn’t appear to address the rising premium payments that we’re seeing.”

ACA implications

The plan’s silence on extending ACA enhanced subsidies has amplified concerns that millions could face higher costs or lose coverage altogether.

Edwin Park, a research professor at Georgetown University’s McCourt School of Public Policy, said in a Guardian report that the framework “clearly opposes extension of the expiring ACA marketplace subsidies,” warning that “roughly 4 million people will end up uninsured and many millions more will see their marketplace premiums double or increase by even more.”

Bipartisan talks in the Senate to revive the subsidies are continuing, with some lawmakers expressing cautious optimism.

Still, experts warn that without concrete legislative action, the Great Healthcare Plan may struggle to move beyond rhetoric.

The post Why analysts are not impressed with Trump’s ‘Great Healthcare Plan’ appeared first on Invezz

0 comment
0
FacebookTwitterPinterestEmail

previous post
Why CEOs and CISOs are split on AI-driven cyber risk
next post
Analyst explains why Indian stocks may sell off after the budget announcement

related articles

Three cybersecurity names Josh Brown added to his...

May 21, 2026

Meta stock struggles in 2026: is a second-half...

May 21, 2026

Dow rises 278 Points as stocks rebound on...

May 21, 2026

Needham says Polaris Forge 3 lease agreement could...

May 21, 2026

Bloom Energy stock soars on AI deal: can...

May 21, 2026

USA Rare Earth stock jumps as DOE funding...

May 21, 2026

Dow reverses early losses as US-Iran deal hopes...

May 21, 2026

SpaceX offering IPO access to retail investors: democracy...

May 21, 2026

Why Spotify stock is surging 14% today?

May 21, 2026

Why is Nio stock falling despite revenue surge...

May 21, 2026
Enter Your Information Below To Receive Free Trading Ideas, Latest News, And Articles.


Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest News

  • War-torn regions have keen interest in US elections

    October 30, 2024
  • Hundreds of Russian shadow tankers trigger military alarm transiting NATO waters: report

    February 26, 2026
  • ‘Held accountable’: Sen. Rand Paul again vows to issue a criminal referral for Fauci

    July 14, 2025
  • Why are UPS, FedEx stocks falling today?

    May 4, 2026
  • Vance calls Psaki comments about wife Usha ‘disgraceful’

    October 23, 2025

Popular Posts

  • 1

    District judges’ orders blocking Trump agenda face hearing in top Senate committee

    April 2, 2025
  • 2

    Secret Service admits leaning on ‘state and local partners’ after claim it ignored Trump team’s past requests

    July 21, 2024
  • 3

    Five more House Democrats call on Biden to drop out, third US senator

    July 19, 2024
  • 4

    CoreWeave eyes $1.5B bond raise to ease debt load following lacklustre IPO: report

    May 9, 2025
  • 5

    Forex Profit Calculator: Maximize Your Trading Potential

    July 10, 2024

Categories

  • Economy (829)
  • Editor's Pick (8,521)
  • Investing (2,690)
  • Stock (1,028)

Latest Posts

  • How a second Trump presidency could impact electric vehicles and clean energy policies

    July 25, 2024
  • Dow futures rise over 400 points: 5 things to know before market opens

    March 31, 2026
  • LIZ PEEK: Hillary is finally paying dearly for dirty tricks that hurt Trump and American voters

    August 5, 2025

Recent Posts

  • Is BP Share Price Undervalued? A Buyer’s Guide

    August 13, 2024
  • Biden pardons late Black activist Marcus Garvey, 4 others

    January 19, 2025
  • Trump’s pick for UN ambassador hailed by Israeli minister as ‘warrior against antisemitism’

    January 24, 2025

Editor’s Pick

  • FTSE 100 edges higher as Iran diplomacy lifts banks and cyclicals

    April 21, 2026
  • Trump admin exit from UN, international organizations raises question of who’s next

    January 13, 2026
  • Is Taiwan Semiconductor stock a buy? Key takeaways from strong Q2 and 2024 guidance

    July 18, 2024
  • About us
  • Contacts
  • Privacy Policy
  • Terms & Conditions

Disclaimer: moneyrisetoday.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2025 moneyrisetoday.com | All Rights Reserved

Money Rise Today – Investing and Stock News
  • Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock